Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
134 hedge funds and large institutions have $1.33B invested in Alder Biopharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 55 increasing their positions, 39 reducing their positions, and 23 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
41% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 39
8% more capital invested
Capital invested by funds: $1.23B → $1.33B (+$101M)
7% more call options, than puts
Call options by funds: $3.69M | Put options by funds: $3.43M
4% less funds holding
Funds holding: 140 → 134 (-6)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$44.4M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$26.5M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$21.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$24.2M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$16.8M |
| 3 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$13.7M |
| 4 |
Morgan Stanley
New York
|
-$7.64M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$5.63M |
ALDR Hedge Fund Activity: Q4 2015 in Review
134 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q4 2015, worth a combined $1.33B — up 8.2% from $1.23B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ALDR and 18 opened new positions — a net loss of 5 holders — while 39 trimmed existing stakes and 55 added.
The largest buyer was Wellington Management Group, adding an estimated $44.4M. The largest seller was Millennium Management, cutting an estimated $24.2M.
- 134 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q4 2015, down from 140 in Q3 2015.
- Funds reported $1.33B of Alder Biopharmaceuticals stock for Q4 2015, up 8.2% quarter-over-quarter.
- 18 funds opened new Alder Biopharmaceuticals positions in Q4 2015 and 23 closed out, a net change of -5 holders.
- The largest Alder Biopharmaceuticals buyer in Q4 2015 was Wellington Management Group, an estimated $44.4M added.
- The largest Alder Biopharmaceuticals seller in Q4 2015 was Millennium Management, an estimated $24.2M sold.
Based on aggregated 13F filings for Q4 2015.